Newsroom | Gilead - Gilead Sciences
This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States. Visit …
Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
Jan 22, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
Full Efficacy and Safety Results for Gilead ... - Gilead Sciences
Jul 24, 2024 · – Gilead Commits to Prioritizing Swift Access and Enabling Efficient Paths for Regulatory Approval of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
Feb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product ...
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.
Gilead Strengthens Early Pipeline in Oncology and Inflammation …
May 9, 2023 · “Gilead and XinThera share similar missions to discover new therapies to treat cancer and inflammatory diseases, which drive our determination to unlock the body’s ability to better respond to these diseases,” said Chris LeMasters, who served as XinThera CEO.
Gilead and Assembly Biosciences Establish Partnership to Develop …
Oct 17, 2023 · “Advancing the next wave of innovation in virology remains a core focus for Gilead as we seek to address the unmet needs of people affected by serious viral infections around the world,” said Tomas Cihlar, Senior Vice President of Virology Research, Gilead.
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for …
Aug 14, 2024 · Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA Back – First and Only Treatment to Demonstrate Statistically Significant Reductions Across Key Biomarkers, ALP Normalization and Pruritus Versus Placebo –
Gilead’s Innovative HIV Treatment Research Pipeline Aims to …
Mar 5, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.